Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Nyxoah S.A.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NYXOAH ANNOUNCES PRELIMINARY RESULTS FOR THE SECOND QUARTER OF 2025 MONT-SAINT-GUIBERT, BELGIUM  AUGUST 11, 2025, 7:00AM CET / 1:00AM ET  NYXOAH SA (EURONEXT BRUSSELS/NASDAQ: NYXH)(NYXOAH OR THE COMPANY), A MEDICAL TECHNOLOGY COMPANY THAT DEVELOPS BREAKTHROUGH TREATMENT ALTERNATIVES FOR OBSTRUCTIVE SLEEP APNEA (OSA), TODAY ANNOUNCED CERTAIN PRELIMINARY, UNAUDITED FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2025 AND OTHER BUSINESS UPDATES. PRELIMINARY, UNAUDITED SECOND QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATES ANNOUNCED ON AUGUST 8, 2025, THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED THE GENIO SYSTEM FOR A SUBSET OF ADULT PATIENTS WITH MODERATE TO SEVERE OSA WITH AN APNEA-HYPOPNEA INDEX (AHI) OF GREATER THAN OR EQUAL TO 15 AND LESS THAN OR EQUAL TO 65.

NYXOAH ANNOUNCES PRELIMINARY RESULTS FOR THE SECOND QUARTER OF 2025

INSIDE INFORMATION REGULATED INFORMATION NYXOAH RECEIVES APPROVAL FROM FDA FOR GENIO SYSTEM FOR THE TREATMENT OF OBSTRUCTIVE SLEEP APNEA U.S. COMMERCIALIZATION OFFICIALLY LAUNCHED MONT-SAINT-GUIBERT, BELGIUM  AUGUST 8, 2025, 10:10PM CET / 4:10PM ET  NYXOAH SA (EURONEXT BRUSSELS/NASDAQ: NYXH) (NYXOAH OR THE COMPANY), A MEDICAL TECHNOLOGY COMPANY THAT DEVELOPS BREAKTHROUGH TREATMENT ALTERNATIVES FOR OBSTRUCTIVE SLEEP APNEA (OSA) THROUGH NEUROMODULATION, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED THE GENIO SYSTEM FOR A SUBSET OF PATIENTS WITH MODERATE TO SEVERE OSA WITH AN APNEA-HYPOPNEA INDEX (AHI) OF GREATER THAN OR EQUAL TO 15 AND LESS THAN OR EQUAL TO 65. GENIO IS A DIFFERENT APPROACH TO HYPOGLOSSAL NERVE STIMULATION (HGNS) FOR THE TREATMENT OF OSA.

NYXOAH RECEIVES APPROVAL FROM FDA FOR GENIO SYSTEM FOR THE TREATMENT OF OBSTRUCTIVE SLEEP APNEA

NYXOAH TO RELEASE SECOND QUARTER 2025 FINANCIAL RESULTS ON AUGUST 18, 2025

NYXOAH'S DREAM PIVOTAL STUDY DATA PUBLISHED IN THE JOURNAL OF CLINICAL SLEEP MEDICINE MONT-SAINT-GUIBERT, BELGIUM  JULY 28, 2025, 10:05PM CET / 4:05PM ET  NYXOAH SA (EURONEXT BRUSSELS/NASDAQ: NYXH)(NYXOAH OR THE COMPANY), A MEDICAL TECHNOLOGY COMPANY THAT DEVELOPS BREAKTHROUGH TREATMENT ALTERNATIVES FOR OBSTRUCTIVE SLEEP APNEA (OSA), TODAY ANNOUNCED THAT DATA FROM ITS DREAM PIVOTAL STUDY WAS PUBLISHED ONLINE IN THE JOURNAL OF CLINICAL SLEEP MEDICINE. THE DREAM PIVOTAL STUDYPRESENTS COMPREHENSIVE 12-MONTH SAFETY AND EFFICACY RESULTS THAT SUPPORTED THE COMPANY'S PMA SUBMISSION TO THE FDA.

NYXOAH'S DREAM PIVOTAL STUDY DATA PUBLISHED IN THE JOURNAL OF CLINICAL SLEEP MEDICINE

REGULATED INFORMATION JUNE 13, 2025, 7:00AM CET / 1:00AM ET NYXOAH SA (EURONEXT BRUSSELS/NASDAQ: NYXH) RUE EDOUARD BELIN 12, 1435 MONT-SAINT-GUIBERT, BELGIUM(HEREINAFTER THE COMPANY) INVITATION TO ATTEND THE EXTRAORDINARY SHAREHOLDERS' MEETING OF THE COMPANY TO BE HELD ON JULY 2, 2025 THE BOARD OF DIRECTORS OF THE COMPANY IS PLEASED TO INVITE ITS SECURITIES HOLDERS TO ATTEND THE EXTRAORDINARY SHAREHOLDERS' MEETING OF THE COMPANY, TO BE HELD ON WEDNESDAY, JULY 2, 2025 AT 2:00P.M. CET AT THE COMPANY'S SEAT, OR AT SUCH OTHER PLACE AS WILL BE INDICATED PRIOR TO SUCH TIME.

INVITATION TO ATTEND THE EXTRAORDINARY SHAREHOLDERS' MEETING OF THE COMPANY TO BE HELD ON JULY 2, 2025

NYXOAH TO PRESENT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE MONT-SAINT-GUIBERT, BELGIUM  MAY 28, 2025, 10:30PM CET / 4:30PM ET  NYXOAH SA (EURONEXT BRUSSELS/NASDAQ: NYXH) (NYXOAH OR THE COMPANY), A MEDICAL TECHNOLOGY COMPANY THAT DEVELOPS BREAKTHROUGH TREATMENT ALTERNATIVES FOR OBSTRUCTIVE SLEEP APNEA (OSA), TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE, WHICH TAKES PLACE JUNE 3  5, 2025 IN NEW YORK. OLIVIER TAELMAN, NYXOAH'S CHIEF EXECUTIVE OFFICER, WILL DELIVER A CORPORATE PRESENTATION ON TUESDAY, JUNE 4, 2025, AT 4:55PM ET.

NYXOAH TO PRESENT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE

NEW YORK, NY / ACCESS NEWSWIRE / MAY 16, 2025 / NEW YORK, NY / ACCESSWIRE / MAY 14, 2025 / POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF NYXOAH S.A. ("NYXOAH" OR THE "COMPANY") (NASDAQ:NYXH).

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF NYXOAH S.A. - NYXH

NEW YORK CITY, NY / ACCESS NEWSWIRE / MAY 14, 2025 / POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF NYXOAH S.A. ("NYXOAH" OR THE "COMPANY") (NASDAQ:NYXH).

REGULATED INFORMATION NYXOAH REPORTS FIRST QUARTER FINANCIAL AND OPERATING RESULTS COMPANY ON TRACK FOR ANTICIPATED PMA APPROVAL IN THE SECOND QUARTER OF 2025 SUCCESSFULLY COMPLETED FDA VALIDATION REQUIREMENTS, FINAL SITE INSPECTION IN PROGRESS MONT-SAINT-GUIBERT, BELGIUM  MAY 14, 2025, 7AM CET / 1AM ET  NYXOAH SA (EURONEXT BRUSSELS/NASDAQ: NYXH) (NYXOAH OR THE COMPANY), A MEDICAL TECHNOLOGY COMPANY THAT DEVELOPS BREAKTHROUGH TREATMENT ALTERNATIVES FOR OBSTRUCTIVE SLEEP APNEA (OSA) THROUGH NEUROMODULATION, TODAY REPORTED FINANCIAL AND OPERATING RESULTS FOR THE FIRST QUARTER OF 2025. RECENT FINANCIAL AND OPERATING HIGHLIGHTS RECEIVED AN FDA APPROVABLE LETTER INDICATING THE FDA WILL APPROVE THE COMPANY'S PMA APPLICATION FOR ITS GENIO SYSTEM SUBJECT TO SATISFACTORY COMPLETION OF A MANUFACTURING FACILITIES, METHODS AND CONTROLS REVIEW SUCCESSFULLY COMPLETED FDA VALIDATION REQUIREMENTS, FINAL SITE INSPECTION IN PROGRESS AT THE U.S. CONTRACT MANUFACTURING SITE REVENUE FOR THE FIRST QUARTER OF 2025 WAS 1.1 MILLION, COMPARED TO 1.2 MILLION IN THE FIRST QUARTER OF 2024 LAUNCHED GENIO 2.1 PATIENT SOFTWARE UPGRADE IN INTERNATIONAL COMMERCIAL MARKETS CASH, CASH EQUIVALENTS AND FINANCIAL ASSETS WERE 63.0 MILLION AT MARCH 31, 2025, COMPARED TO 85.6 MILLION AT THE END OF 2024 "WE ARE EXCITED THAT WE ARE IN THE FINAL STAGE OF THE FDA REVIEW PROCESS OF OUR GENIO SYSTEM IN THE UNITED STATES," COMMENTED OLIVIER TAELMAN, NYXOAH'S CHIEF EXECUTIVE OFFICER.

NYXOAH REPORTS FIRST QUARTER FINANCIAL AND OPERATING RESULTS

NEW YORK, MAY 13, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF NYXOAH S.A. (NYXOAH OR THE COMPANY) (NASDAQ: NYXH). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

Nyxoah S.A.

NYXH

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Nyxoah S.A.

NYXH.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

NYXH